Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.42 USD

91.42
364,986

-0.16 (-0.18%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise

Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.

AtriCure (ATRC) Gains China Approval for AtriClip LAA System

AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.

HAE vs. BSX: Which Stock Is the Better Value Option?

HAE vs. BSX: Which Stock Is the Better Value Option?

Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings

FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.

Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook

Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.

HAE or BSX: Which Is the Better Value Stock Right Now?

HAE vs. BSX: Which Stock Is the Better Value Option?

Elanco (ELAN) Stock Declines After Sale of Aqua Business

Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Globus Medical (GMED) Global Sales, Innovation Aid Growth

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Patterson (PDCO) Expands AI Solutions in Canada via Alliance

Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions

Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note

QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.

McKesson (MCK) Gains 26% Year to Date: What's Backing the Rally?

McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.

Masimo (MASI) Sues Politan for Misstatements, Delays Annual Meet

Masimo (MASI) sues Politan to correct material misstatements in an ongoing proxy battle, rescheduling its annual meeting. Politan denies allegations and vows to prevent any further delay, criticizing Masimo's tactics.

Here's Why Haemonetics (HAE) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop

Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.

Integra's (IART) New Site to Produce Recalled Tissue Products

Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.

Should You Keep Chemed (CHE) Stock in Your Portfolio Now?

Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.

Alcon (ALC) Rides on Innovation, Balanced Segmental Sales

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.